<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409237</url>
  </required_header>
  <id_info>
    <org_study_id>NMD-50/18</org_study_id>
    <nct_id>NCT03409237</nct_id>
  </id_info>
  <brief_title>Coagulation Activation by Hyperosmolar Agents in Intracranial Hypertension</brief_title>
  <official_title>Evaluation of Coagulation Activation in Patients With Intracranial Hypertension After Treatment With Mannitol or Hypertonic Saline Solution.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osmotherapy consists in the therapeutic use of osmotically active substances with the aim of
      reducing the volume and therefore the intracranial pressure. It therefore represents an
      essential component in the clinical management of cerebral edema and intracranial
      hypertension, whether they are a consequence of head trauma, ischemic or hemorrhagic stroke,
      and neoplasm or neurosurgical procedures.

      The current study aims at evaluating in vivo the effects on haemostasis parameters of
      hypertonic saline solutions at different concentration, as compared to mannitol, in patients
      with neuroradiological signs (CT / MRI) of cerebral edema / non-traumatic intracranial
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osmotherapy is commonly used in the treatment of intracranial hypertension (ICH) due to a
      variety of causes, including head trauma, intracranial neoplasia, infection or hemorrhage,
      and status epilepticus. The principle goal of osmotherapy is to shift fluid from the
      intracellular into the extracellular compartment using intravenous hyperosmolar agents,
      thereby reducing brain edema and improving cerebral perfusion pressure. Although 10-20%
      mannitol is considered the gold standard hyperosmolar agent in the treatment of ICH,
      mannitol-induced osmotic diuresis may cause hypovolemia and reduction in cerebral perfusion
      pressure. In recent years, 3.0-7.5% hypertonic saline (HTS) has gained popularity in the
      treatment of ICH as it has less pronounced diuretic effects and therefore does not cause
      hypovolemia. Indeed, in the face of hypovolemic shock and traumatic brain injury, HTS
      provides the advantage of volume expansion, restoring adequate cerebral perfusion pressures,
      and reducing brain edema, which makes it superior to mannitol in trauma patients with shock.

      Both mannitol and HTS have been shown to interfere with whole blood coagulation and platelet
      function. This is in part due to dilutional coagulopathy. Furthermore, 7.2% HTS may directly
      disturb both fibrin formation and platelet function, and mannitol may interfere with
      coagulation by reducing clot strength. In addition, hyperosmolarity is supposed to lead to
      impairment of both whole blood coagulation and platelet function . In consequence, the safety
      of using these agents in patients with ICH and intracranial hemorrhage remains unclear.
      Previous in vitro studies in humans have demonstrated anticoagulant effects of both mannitol
      and HTS, although one clinical study failed to demonstrate any negative effect on hemostasis
      using either solution in patients undergoing elective intracranial surgery. However, in vivo
      studies in a clinical setting are lacking.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in coagulation parameters</measure>
    <time_frame>Before osmotic therapy (time 0), after 12 hrs infusion (time 1)</time_frame>
    <description>Coagulation parameters such as thrombin and prothrombin time, fibrinogen, thrombin generation time will be measured in plasma by ELISA test or on whole blood by thromboelastography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammation markers</measure>
    <time_frame>Before osmotic therapy (time 0), after 12 hrs infusion (time 1)</time_frame>
    <description>Inflammation markers such as C reactive protein, interleukin 6, P-selectin. E-selectin will be measured in plasma</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intracranial Hypertension</condition>
  <condition>Cerebral Edema</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Mannitol 0.2-0.3 g/kg 4 times/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Hypertonic saline solution 3%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Hypertonic solution saline 4%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Hypertonic saline solution 7%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity &lt;320.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline solution</intervention_name>
    <description>Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity &lt;320.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients (men and women) with cerebral edema / intracranial hypertension (CT / MRI
        neuroradiological diagnosis) on a non-traumatic basis with indication to osmotic therapy,
        treated on the basis of clinical and radiological evidence according to current treatment
        standards and meeting the inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication to osmotic therapy for cerebral edema / non-traumatic intracranial
             hypertension

          -  Age 18 - 80 years

          -  Body temperature between 35.5 ° C and 37.5 °C

        Exclusion Criteria:

          -  Congenital or acquired disorders of hemostasis

          -  Clinical history of abnormal bleeding

          -  Hematologic or Renal diseases (acute or chronic renal failure II-III stage)

          -  Chronic or recent therapy with antiplatelet and/or anticoagulants

          -  Taking corticosteroids or nonsteroidal anti-inflammatory drugs (less than 4 weeks)

          -  Administration of macromolecular vascular filling solutions (less than 4 weeks)

          -  History of recent venous / arterial thromboembolic disease (less than three months)

          -  Moderate-severe liver dysfunction

          -  Anemia (hb &lt;10 mg/dl)

          -  Recent transfusions (less than three months)

          -  Hyponatremia (Na &lt;135 meq/l)

          -  Hypernatremia (Na&gt; 155 meq/l)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Licia Iacoviello, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS Neuromed</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fulvio Aloj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Neuromed</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Licia Iacoviello, MD, PhD</last_name>
    <phone>+393485108779</phone>
    <email>licia.iacoviello@moli-sani.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giovanni de Gaetano, MD, PhD</last_name>
    <phone>+393355914217</phone>
    <email>giovanni.degaetano@moli-sani.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS INM Neuromed, Department of Epidemiology and Prevention</name>
      <address>
        <city>Pozzilli</city>
        <state>IS</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Torre-Healy A, Marko NF, Weil RJ. Hyperosmolar therapy for intracranial hypertension. Neurocrit Care. 2012 Aug;17(1):117-30. doi: 10.1007/s12028-011-9649-x. Review.</citation>
    <PMID>22090171</PMID>
  </reference>
  <reference>
    <citation>Ropper AH. Hyperosmolar therapy for raised intracranial pressure. N Engl J Med. 2012 Aug 23;367(8):746-52. doi: 10.1056/NEJMct1206321. Review.</citation>
    <PMID>22913684</PMID>
  </reference>
  <reference>
    <citation>Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care, AANS/CNS, Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons SD, Ullman JS, Videtta W, Wilberger JE, Wright DW. Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J Neurotrauma. 2007;24 Suppl 1:S14-20. Erratum in: J Neurotrauma. 2008 Mar;25(3):276-8. multiple author names added.</citation>
    <PMID>17511539</PMID>
  </reference>
  <reference>
    <citation>White H, Cook D, Venkatesh B. The use of hypertonic saline for treating intracranial hypertension after traumatic brain injury. Anesth Analg. 2006 Jun;102(6):1836-46. Review.</citation>
    <PMID>16717334</PMID>
  </reference>
  <reference>
    <citation>Prough DS, Whitley JM, Taylor CL, Deal DD, DeWitt DS. Regional cerebral blood flow following resuscitation from hemorrhagic shock with hypertonic saline. Influence of a subdural mass. Anesthesiology. 1991 Aug;75(2):319-27.</citation>
    <PMID>1677548</PMID>
  </reference>
  <reference>
    <citation>Schmoker JD, Zhuang J, Shackford SR. Hypertonic fluid resuscitation improves cerebral oxygen delivery and reduces intracranial pressure after hemorrhagic shock. J Trauma. 1991 Dec;31(12):1607-13.</citation>
    <PMID>1749030</PMID>
  </reference>
  <reference>
    <citation>Mojtahedzadeh M, Ahmadi A, Mahmoodpoor A, Beigmohammadi MT, Abdollahi M, Khazaeipour Z, Shaki F, Kuochaki B, Hendouei N. Hypertonic saline solution reduces the oxidative stress responses in traumatic brain injury patients. J Res Med Sci. 2014 Sep;19(9):867-74.</citation>
    <PMID>25535502</PMID>
  </reference>
  <reference>
    <citation>Munar F, Ferrer AM, de Nadal M, Poca MA, Pedraza S, Sahuquillo J, Garnacho A. Cerebral hemodynamic effects of 7.2% hypertonic saline in patients with head injury and raised intracranial pressure. J Neurotrauma. 2000 Jan;17(1):41-51.</citation>
    <PMID>10674757</PMID>
  </reference>
  <reference>
    <citation>Rabinovici R, Yue TL, Krausz MM, Sellers TS, Lynch KM, Feuerstein G. Hemodynamic, hematologic and eicosanoid mediated mechanisms in 7.5 percent sodium chloride treatment of uncontrolled hemorrhagic shock. Surg Gynecol Obstet. 1992 Oct;175(4):341-54.</citation>
    <PMID>1411892</PMID>
  </reference>
  <reference>
    <citation>Wilder DM, Reid TJ, Bakaltcheva IB. Hypertonic resuscitation and blood coagulation: in vitro comparison of several hypertonic solutions for their action on platelets and plasma coagulation. Thromb Res. 2002 Sep 1;107(5):255-61.</citation>
    <PMID>12479887</PMID>
  </reference>
  <reference>
    <citation>Tan TS, Tan KH, Ng HP, Loh MW. The effects of hypertonic saline solution (7.5%) on coagulation and fibrinolysis: an in vitro assessment using thromboelastography. Anaesthesia. 2002 Jul;57(7):644-8.</citation>
    <PMID>12059821</PMID>
  </reference>
  <reference>
    <citation>Reed RL 2nd, Johnston TD, Chen Y, Fischer RP. Hypertonic saline alters plasma clotting times and platelet aggregation. J Trauma. 1991 Jan;31(1):8-14.</citation>
    <PMID>1986137</PMID>
  </reference>
  <reference>
    <citation>Delano MJ, Rizoli SB, Rhind SG, Cuschieri J, Junger W, Baker AJ, Dubick MA, Hoyt DB, Bulger EM. Prehospital Resuscitation of Traumatic Hemorrhagic Shock with Hypertonic Solutions Worsens Hypocoagulation and Hyperfibrinolysis. Shock. 2015 Jul;44(1):25-31. doi: 10.1097/SHK.0000000000000368.</citation>
    <PMID>25784523</PMID>
  </reference>
  <reference>
    <citation>Ng KF, Lam CC, Chan LC. In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial. Br J Anaesth. 2002 Apr;88(4):475-80.</citation>
    <PMID>12066721</PMID>
  </reference>
  <reference>
    <citation>Rhind SG, Crnko NT, Baker AJ, Morrison LJ, Shek PN, Scarpelini S, Rizoli SB. Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients. J Neuroinflammation. 2010 Jan 18;7:5. doi: 10.1186/1742-2094-7-5.</citation>
    <PMID>20082712</PMID>
  </reference>
  <reference>
    <citation>Luostarinen T, Niiya T, Schramko A, Rosenberg P, Niemi T. Comparison of hypertonic saline and mannitol on whole blood coagulation in vitro assessed by thromboelastometry. Neurocrit Care. 2011 Apr;14(2):238-43. doi: 10.1007/s12028-010-9475-6.</citation>
    <PMID>21369792</PMID>
  </reference>
  <reference>
    <citation>Hanke AA, Maschler S, Schöchl H, Flöricke F, Görlinger K, Zanger K, Kienbaum P. In vitro impairment of whole blood coagulation and platelet function by hypertonic saline hydroxyethyl starch. Scand J Trauma Resusc Emerg Med. 2011 Feb 10;19:12. doi: 10.1186/1757-7241-19-12.</citation>
    <PMID>21310047</PMID>
  </reference>
  <reference>
    <citation>Gatidis S, Borst O, Föller M, Lang F. Effect of osmotic shock and urea on phosphatidylserine scrambling in thrombocyte cell membranes. Am J Physiol Cell Physiol. 2010 Jul;299(1):C111-8. doi: 10.1152/ajpcell.00477.2009. Epub 2010 Mar 17.</citation>
    <PMID>20237147</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Licia Iacoviello</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Intracranial Hypertension</mesh_term>
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

